	US 12,029,709 B2
	Inhalable epinephrine formulation
John Fraser, Windsor (AU); Sean Mark Dalziel, Windsor (AU); Teresa Iley, Hertfordshire (GB); Jonathan Brazier, Hertfordshire (GB); Patrick Joseph Lynch, Windsor (AU); John Fredatovich, Windsor (AU); and Benjamin Barnaby Trout, Windsor (AU)
Assigned to De Motu Cordis Pty Ltd, Queensland (AU)
Filed by De Motu Cordis Pty Ltd, Windsor (AU)
Filed on Aug. 11, 2022, as Appl. No. 17/886,124.
Prior Publication US 2024/0050382 A1, Feb. 15, 2024
Int. Cl. A61K 31/137 (2006.01); A61K 9/00 (2006.01); A61K 47/26 (2006.01)

CPC A61K 31/137 (2013.01) [A61K 9/0075 (2013.01); A61K 47/26 (2013.01)]

10 Claims

1. A dry powder inhalable formulation consisting of:

(i) crystalline epinephrine bitartrate; and

(ii) crystalline α-lactose monohydrate present at between about 50% w/w and about 99% w/w of the entire formulation,

wherein the dry powder inhalable formulation is formulated for inhalation by negative pressure.